Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
Phase 3positiveTam-PelitopotecanPositive
AI Analysis
Summary
Phase III TAISHAN-302 trial demonstrates that Tam-Peli (tambotatug pelitecan), an anti-B7-H3 antibody-drug conjugate, significantly improved survival in relapsed small-cell lung cancer, reducing death risk by 54% compared to topotecan and improving progression-free survival and response rates.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
54% reduction in risk of death versus topotecan; improved progression-free survival and response rates
Importance:8/10
Sentiment:
0.85
Phase 3oncologylung cancersmall-cell lung cancerantibody-drug conjugatesurvival benefitclinical trial
Read the original article
Published by PR Newswire Clinical Trials on September 13, 2026 12:57 PM